Consensus

← vista completa

Published on January 1, 2010 | http://doi.org/10.5867/medwave.2010.01.4354

Review of the literature on treatment of locally advanced breast cancer

Revisión de la literatura sobre tratamiento del cáncer de mama localmente avanzado

Garbiñe Ballesteros, Mónica Campos, Bettina Müller, Ana María Ciudad, Luis Alberto Orlandi, Ana María Donoso, María Eugenia Bravo, Mauricio Camus, César del Castillo, Hernán Pulgar, Carolina Barriga

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Garbiñe Ballesteros

Sociedad Chilena de Mastología

Mónica Campos

Sociedad Chilena de Mastología

Bettina Müller

Sociedad Chilena de Mastología

Ana María Ciudad

Sociedad Chilena de Mastología

Luis Alberto Orlandi

Sociedad Chilena de Mastología

Ana María Donoso

Sociedad Chilena de Mastología

María Eugenia Bravo

Sociedad Chilena de Mastología

Mauricio Camus

Sociedad Chilena de Mastología

César del Castillo

Sociedad Chilena de Mastología

Hernán Pulgar

Sociedad Chilena de Mastología

Carolina Barriga

Sociedad Chilena de Mastología

Figures

Article has no figures.

Forum

No messages

History

Citation Ballesteros G, Campos M, Müller B, Ciudad AM, Orlandi LA, Donoso AMet al. Review of the literature on treatment of locally advanced breast cancer. Medwave 2010;10(1):e4354 doi: 10.5867/medwave.2010.01.4354

Submission date 12/08/2009

Acceptance date 26/08/2009

Publication date 01/01/2010

Index

Metrics

Not available at the moment.

Notes

Keywords

tratamiento, localmente avanzado, cáncer de mama

Origin and peer review

con revisión por pares externa

References

  1. Aggarwal V, Agarwal G, Lal P, Krishnani N, Mishra A, Verma AK, et al. Feasibility study of safe breast conservation in large and locally advanced cancers with use of radiopaque markers to mark pre-neoadjuvant chemotherapy tumor margins. World J Surg. 2008 Dec;32(12):2562-9. | CrossRef | PubMed
  2. Aksu G, Kucucuk S, Fayda M, Saynak M, Baskaya S, Saip P, et al. The role of postoperative radiotherapy in node negative breast cancer patients with pT3-T4 disease. Eur J Surg Oncol. 2007 Apr;33(3):285-93. Epub 2006 Dec 4. | CrossRef | PubMed
  3. Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist. 2006 Jun;11(6):563-73. | CrossRef | PubMed
  4. Arriagada R, Lê MG. Number of positive axillary lymph nodes and post-mastectomy radiotherapy effect in breast cancer patients. Radiother Oncol. 2007 Jul;84(1):102-3; discussion 103-4; author reply 104-5. Epub 2007 Jun 11. | CrossRef | PubMed
  5. Arthur DW, Schmidt-Ullrich RK, Friedman RB, Wazer DE, Kachnic LA, Amir C, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):289-96. | CrossRef | PubMed
  6. Azria D, Ozsahin M, Gligorov J, Zaman K, Llacer Moscardo C, Lemanski C, et al. How to combine hormonotherapy and radiation treatment in adjuvant breast cancer? Cancer Radiother. 2008 Jan;12(1):37-41. Epub 2008 Jan 8. | CrossRef | PubMed
  7. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10. | CrossRef | PubMed
  8. Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):393-7. | CrossRef | PubMed
  9. Ben Ammar CN, Kochbati L, Chraeit N, Amrouche A, Gargouri W, Frikha H, et al. Should chest wall irradiation be included after mastectomy and negative node breast cancer? Cancer Radiother. 2008 Mar;12(2):73-7. Epub 2008 Feb 20. | PubMed
  10. Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev. 2007 Feb;33(1):48-57. Epub 2006 Nov 28. | CrossRef | PubMed
  11. Berruti A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, et al. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist. 2008 Nov;13(11):1137-48. Epub 2008 Nov 7. | CrossRef | PubMed
  12. Bristol IJ, Buchholz TA. Inflammatory breast cancer: current concepts in local management. Breast Dis. 2005-2006;22:75-83. | PubMed
  13. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):474-84. Epub 2008 Apr 24. | CrossRef | PubMed
  14. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, et al. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1155-60. Epub 2006 Jun 5. | CrossRef | PubMed
  15. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15;19(8):2240-6. | PubMed
  16. Buzdar AU. Preoperative chemotherapy treatment of breast cancer--a review. Cancer. 2007 Dec 1;110(11):2394-407. | CrossRef | PubMed
  17. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov;17(11):3412-7. | PubMed
  18. Calitchi E, Kirova YM, Otmezguine Y, Feuilhade F, Piedbois Y, Le Bourgeois JP. Long-term results of neoadjuvant radiation therapy for breast cancer. Int J Cancer. 2001 Aug 20;96(4):253-9. | CrossRef | PubMed
  19. Campos M, Del Castillo C.Cancer de Mama Localmente avanzado: tratamiento combinado. [Presentación en congreso]
  20. Cariati M, Bennett-Britton TM, Pinder SE, Purushotham AD. "Inflammatory" breast cancer. Surg Oncol. 2005 Nov;14(3):133-43. Epub 2005 Sep 9. | CrossRef | PubMed
  21. Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, et al. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1043-51. | CrossRef | PubMed
  22. Chawla AK, Kachnic LA, Taghian AG, Niemierko A, Zapton DT, Powell SN. Radiotherapy and breast reconstruction: complications and cosmesis with TRAM versus tissue expander/implant. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):520-6. | CrossRef | PubMed
  23. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008 Jan 1;112(1):17-26. | CrossRef | PubMed
  24. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol. 2008 Oct 20;26(30):4981-9. Epub 2008 Aug 18. | CrossRef | PubMed
  25. Chen SC, Chang HK, Lin YC, Hsueh S, Cheung YC, Leung WM, et al. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Jpn J Clin Oncol. 2008 Feb;38(2):99-105. Epub 2008 Feb 12. | CrossRef | PubMed
  26. Cheng SH, Horng CF, Clarke JL, Tsou MH, Tsai SY, Chen CM, et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1401-9. Epub 2006 Feb 10. | CrossRef | PubMed
  27. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008 Feb 10;26(5):786-90. | CrossRef | PubMed
  28. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009 Feb 10;27(5):726-32. Epub 2008 Dec 29. | CrossRef | PubMed
  29. Clouth B, Chandrasekharan S, Inwang R, Smith S, Davidson N, Sauven P. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. Eur J Surg Oncol. 2007 Oct;33(8):961-6. Epub 2007 Jan 9. | CrossRef | PubMed
  30. Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol. 2006 Mar;17(3):409-14. Epub 2005 Dec 6. | CrossRef | PubMed
  31. Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006 Apr;13(4):483-90. Epub 2006 Mar 7. | CrossRef | PubMed
  32. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8(2):141-8. | CrossRef | PubMed
  33. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 1;110(7):1436-44. | CrossRef | PubMed
  34. Curcio LD, Rupp E, Williams WL, Chu DZ, Clarke K, Odom-Maryon T, et al. Beyond palliative mastectomy in inflammatory breast cancer--a reassessment of margin status. Ann Surg Oncol. 1999 Apr-May;6(3):249-54. | CrossRef | PubMed
  35. D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, et al. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J. 2008 Sep-Oct;14(5):435-41. | CrossRef | PubMed
  36. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer. 2007 Sep 15;110(6):1195-200. | CrossRef | PubMed
  37. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer. 2008 May 1;112(9):1905-11. | CrossRef | PubMed
  38. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4899-905. Epub 2008 Sep 15. | CrossRef | PubMed
  39. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol. 2007 Jun;18(6):997-1003. Epub 2007 Mar 17. | CrossRef | PubMed
  40. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008 Sep 20;26(27):4449-57. Epub 2008 Jul 14. | CrossRef | PubMed
  41. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN; et al. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer. 2008 Oct 15;113(8 Suppl):2315-24. | CrossRef | PubMed
  42. El-Tamer M, Hussain S, Weedon J, Chalchal H, Chakrabarti A, Sohn C, et al. Prognoses of T4 breast cancer subsets. Ann Surg Oncol. 2002 May;9(4):340-5. | CrossRef | PubMed
  43. Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, et al. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol. 2008 Sep;19(9):1573-7. Epub 2008 Jun 13. | CrossRef | PubMed
  44. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005 May 1;23(13):2988-95. | CrossRef | PubMed
  45. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002 Aug 22;347(8):567-75. | CrossRef | PubMed
  46. Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, et al. Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Res Treat. 2007 May;103(1):45-52. Epub 2007 Apr 7. | CrossRef | PubMed
  47. Floyd SR, Buchholz TA, Haffty BG, Goldberg S, Niemierko A, Raad RA, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):358-64. Epub 2006 Aug 2. | CrossRef | PubMed
  48. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008 Oct 10;26(29):4746-51. Epub 2008 Aug 11. | CrossRef | PubMed
  49. Garimella V, Qutob O, Fox JN, Long ED, Chaturvedi A, Turnbull LW, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007 Mar;33(2):157-61. Epub 2006 Nov 7. | CrossRef | PubMed
  50. Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003;8(6):521-30. | CrossRef | PubMed
  51. Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res. 2003;5(6):284-8. Epub 2003 Aug 26. | CrossRef | PubMed
  52. Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007 Oct 15;110(8):1687-96. | CrossRef | PubMed
  53. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007 Aug;12(8):904-12. | CrossRef | PubMed
  54. Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008 Feb 10;26(5):696-7. | CrossRef | PubMed
  55. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 1;24(7):1037-44. | CrossRef | PubMed
  56. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200-8. | CrossRef | PubMed
  57. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10;24(26):4236-44. Epub 2006 Aug 8. | CrossRef | PubMed
  58. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet. 1999 Oct 23;354(9188):1425-30. | CrossRef | PubMed
  59. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006 Apr 20;24(12):1831-8. Epub 2006 Mar 20. | CrossRef | PubMed
  60. Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008 Jun 15;112(12):2646-54. | CrossRef | PubMed
  61. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug;18(15):2817-27. | PubMed
  62. Kilburn LS; TNT Trial Management Group. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol). 2008 Feb;20(1):35-9. Epub 2007 Oct 31. | CrossRef | PubMed
  63. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008 Mar 20;26(9):1419-26. Epub 2008 Feb 19. | CrossRef | PubMed
  64. Lannin DR, Grube B, Black DS, Ponn T. Breast tattoos for planning surgery following neoadjuvant chemotherapy. Am J Surg. 2007 Oct;194(4):518-20. | CrossRef | PubMed
  65. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol. 2002 Jun 1;20(11):2713-25. | CrossRef | PubMed
  66. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am. 2007 Apr;87(2):379-98, ix. | CrossRef | PubMed
  67. Lelievre L, Houvenaeghel G, Buttarelli M, Brenot-Rossi I, Huiart L, Tallet A, et al. Value of the sentinel lymph node procedure in patients with large size breast cancer. Ann Surg Oncol. 2007 Feb;14(2):621-6. Epub 2006 Nov 12. | CrossRef | PubMed
  68. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J. Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients. Cancer Radiother. 2004 Jun;8(3):155-67. | CrossRef | PubMed
  69. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1191-200. | CrossRef | PubMed
  70. Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006 Nov;13(11):1434-42. Epub 2006 Sep 17. | CrossRef | PubMed
  71. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004 Oct 15;22(20):4067-74. | CrossRef | PubMed
  72. Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, et al. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009 Apr 15;115(8):1605-12. | CrossRef | PubMed
  73. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev. 2008 Oct;34(6):539-57. Epub 2008 May 27. | CrossRef | PubMed
  74. Mathew J, Asgeirsson KS, Agrawal A, Mukherjee A, Ellis IO, Cheung KL, et al. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience. Eur J Surg Oncol. 2007 Oct;33(8):972-6. Epub 2007 Mar 27. | CrossRef | PubMed
  75. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. | CrossRef | PubMed
  76. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May;18(5):874-80. Epub 2007 Feb 10. | CrossRef | PubMed
  77. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1004-9. Epub 2007 Apr 6. | CrossRef | PubMed
  78. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002. | PubMed
  79. Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M. Approach to inflammatory breast cancer. Can Fam Physician. 2009 Jan;55(1):25-31. | PubMed
  80. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002 Apr;9(3):228-34. | CrossRef | PubMed
  81. Oh JL, Nguyen G, Whitman GJ, Hunt KK, Yu TK, Woodward WA, et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007 Dec 1;110(11):2420-7. | CrossRef | PubMed
  82. Oh JL, Dryden MJ, Woodward WA, Yu TK, Tereffe W, Strom EA, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006 Nov 1;24(31):4971-5. | CrossRef | PubMed
  83. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007 Mar;82(3):247-53. Epub 2007 Feb 15. | CrossRef | PubMed
  84. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997 Oct 2;337(14):949-55. | CrossRef | PubMed
  85. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005 Mar 20;23(9):1941-50. | CrossRef | PubMed
  86. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov;13(11):1443-9. Epub 2006 Sep 21. | CrossRef | PubMed
  87. Pierce LJ. The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol. 2005 Mar 10;23(8):1706-17. | CrossRef | PubMed
  88. Poortmans P. Evidence based radiation oncology: breast cancer. Radiother Oncol. 2007 Jul;84(1):84-101. Epub 2007 Jun 27. | CrossRef | PubMed
  89. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer. 2009 Mar 15;115(6):1194-202. | CrossRef | PubMed
  90. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM. HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. Breast Cancer. 2005;12(4):294-8. | CrossRef | PubMed
  91. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26. | CrossRef | PubMed
  92. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999 Jun;17(6):1689-700. | PubMed
  93. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, et al. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):435-40. Epub 2007 Dec 31. | CrossRef | PubMed
  94. Scepanovic D, Bajic N, Babic J. Postmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients. Arch Oncol 2004;12(1):39-43. | CrossRef
  95. Schrenk P, Tausch C, Wölfl S, Bogner S, Fridrik M, Wayand W. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes. Am J Surg. 2008 Aug;196(2):176-83. Epub 2008 May 29. | CrossRef | PubMed
  96. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009 Feb 1;27(4):535-41. Epub 2008 Dec 15. | CrossRef | PubMed
  97. Shafiq J, Delaney G, Barton MB. An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. Radiother Oncol. 2007 Jul;84(1):11-7. Epub 2007 Mar 30. | CrossRef | PubMed
  98. Shien T, Akashi-Tanaka S, Miyakawa K, Hojo T, Shimizu C, Seki K, et al. Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg. 2009 Jan;33(1):44-51. | CrossRef | PubMed
  99. Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol. 2007 Jan;37(1):1-8. Epub 2007 Jan 3. | CrossRef | PubMed
  100. Sinacki M, Jassem J, van Tienhoven G. Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised phase III study (EORTC 10974/22002, LAMANOMA)--why did this study fail? Eur J Cancer. 2005 Dec;41(18):2787-8. Epub 2005 Nov 7. | CrossRef | PubMed
  101. Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol. 2008 Feb;35(1):72-7. | CrossRef | PubMed
  102. Smith BD, Haffty BG, Smith GL, Hurria A, Buchholz TA, Gross CP. Use of postmastectomy radiotherapy in older women. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):98-106. Epub 2007 Nov 8. | PubMed
  103. Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004 May 15;22(10):1839-48. | CrossRef | PubMed
  104. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002 Apr;9(3):235-42. | CrossRef | PubMed
  105. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4. | CrossRef | PubMed
  106. Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. | CrossRef | PubMed
  107. Tai P, Joseph K, Sadikov E, Mahmood S, Lien F, Yu E. Nodal ratios in node-positive breast cancer--long-term study to clarify discrepancy of role of supraclavicular and axillary regional radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):662-6. Epub 2007 Apr 20. | CrossRef | PubMed
  108. Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, et al. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat. 2008 Nov;112(2):309-16. Epub 2007 Dec 14. | CrossRef | PubMed
  109. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2008 Dec;17(4):301-11. Epub 2008 May 7. | CrossRef | PubMed
  110. Tiezzi DG, Andrade JM, Marana HR, Zola FE, Peria FM. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008 Aug;34(8):863-7. Epub 2008 Mar 4. | CrossRef | PubMed
  111. Tsunoda-Shimizu H, Hayashi N, Hamaoka T, Kawasaki T, Tsugawa K, Yagata H, et al. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging. Breast Cancer. 2008;15(2):133-40. | CrossRef | PubMed
  112. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006 Aug;17(8):1228-33. Epub 2006 Jun 1. | CrossRef | PubMed
  113. Valenzuela M, Julian TB. Neo-adjuvant hormonal therapy. Breast J. 2008 May-Jun;14(3):279-83. Epub 2008 Mar 27. | CrossRef | PubMed
  114. Veronesi U, Zurrida S. Optimal Surgical Treatment of Breast Cancer. Oncologist. 1996;1(6):340-346. | PubMed
  115. Veronesi U, Arnone P, Veronesi P, Galimberti V, Luini A, Rotmensz N, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol. 2008 Sep;19(9):1553-60. Epub 2008 May 7. | CrossRef | PubMed
  116. Vilarino-Varela M, Chin YS, Makris A. Current indications for post-mastectomy radiation. Int Semin Surg Oncol. 2009 Feb 9;6:5. | CrossRef | PubMed
  117. von Minckwitz G. Breakthrough for neoadjuvant chemotherapy. Breast Cancer. 2008;15(1):27-30. | CrossRef | PubMed
  118. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003 Apr 1;21(7):1205-13. | CrossRef | PubMed
  119. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000 Mar;18(6):1220-9. | PubMed
  120. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist. 2002;7(3):239-45. | CrossRef | PubMed
  121. Woodward WA, Cristofanilli M. Inflammatory breast cancer. Semin Radiat Oncol. 2009 Oct;19(4):256-65. | CrossRef | PubMed
  122. Wright JL, Cordeiro PG, Ben-Porat L, Van Zee KJ, Hudis C, Beal K, et al. Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):43-50. Epub 2007 Sep 12. | CrossRef | PubMed
  123. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008 Jun;109(3):417-26. Epub 2007 Jul 26. | CrossRef | PubMed
  124. Yarnold J. Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009. Clin Oncol (R Coll Radiol). 2009 Apr;21(3):159-60. Epub 2009 Jan 23. | CrossRef | PubMed
  125. Yu J, Li G, Li J, Wang Y. The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):874-8. | CrossRef | PubMed